Jill Marie Broadfoot - Feb 3, 2023 Form 4 Insider Report for aTYR PHARMA INC (LIFE)

Role
Chief Financial Officer
Signature
/s/ Nancy E. Denyes, attorney-in-fact
Stock symbol
LIFE
Transactions as of
Feb 3, 2023
Transactions value $
-$3,696
Form type
4
Date filed
2/6/2023, 06:00 PM
Previous filing
Jul 15, 2022
Next filing
Feb 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LIFE Common stock Options Exercise +3.75K +28.25% 17K Feb 3, 2023 Direct F1, F2, F3
transaction LIFE Common stock Sale -$3.7K -1.57K -9.2% $2.36 15.5K Feb 6, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIFE Restricted Stock Unit Options Exercise $0 -3.75K -25% $0.00 11.3K Feb 3, 2023 Common Stock 3.75K Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Includes 986 shares acquired under that Company's 2015 Employee Stock Purchase Plan on November 15, 2022.
F4 Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
F5 The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.